This extension study of WA19926 will assess the long-term safety and the efficacy of RoActemra/Actemra (tocilizumab) treatment in patients with rheumatoid arthritis. Patients who have completed the core study WA19926 are eligible to participate. Patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. The anticipated time on study drug is 104 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01649804?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
